BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16025444)

  • 1. Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods.
    Biswas S; Berry DA
    Genet Epidemiol; 2005 Sep; 29(2):141-54. PubMed ID: 16025444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
    Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
    Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility.
    Nixon RM; Duffy SW
    J Cancer Epidemiol Prev; 2002; 7(4):205-12. PubMed ID: 12846491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
    James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
    J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
    Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
    Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.